Literature DB >> 30168890

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses.

Fabien Pitoiset1,2, Lydie Cassard3, Karim El Soufi1,2, Lisa Boselli3, Jonathan Grivel3, Alexandra Roux1,2, David Klatzmann1,2, Nathalie Chaput3,4, Michelle Rosenzwajg1,2.   

Abstract

Multicolor flow cytometry is a technology of choice for phenotyping of immune cells, and it can be used routinely for the follow up of patients in clinical trials. But it is challenging to define combinations of conjugated antibodies that efficiently allow the detailed analysis of major immune cell subsets and the identification of rare cell populations. In a collaborative work among the Immunology, Immunopathology, Immunotherapy (I3 ) laboratory, and the laboratory of immunomonitoring in oncology (L.I.O), we developed and validated 12 different 10-color flow cytometry panels that allow the deep immunophenotyping of cells from whole blood for the follow up of autoimmune and cancer patients. Here, we describe these optimized flow cytometry panels, showing that they provide the advanced analysis of T cells (including regulatory T cells), B cells, NK cells, MAIT cells, myeloid cells, monocytes, and dendritic cells. Most of the panels have been dried to improve standardization of the labeling and the entire procedure can be performed on less than 2 ml of whole blood. These deep immunophenotyping flow cytometry panels constitute a powerful tool for the monitoring of immune blood cells and will hopefully lead to the discovery of new biomarkers and potential therapeutic targets in autoimmune and cancer clinical trials.
© 2018 International Society for Advancement of Cytometry. © 2018 International Society for Advancement of Cytometry.

Entities:  

Keywords:  clinical studies; deep phenotyping; flow cytometry; human immunology; immunomonitoring; immunophenotyping

Mesh:

Substances:

Year:  2018        PMID: 30168890     DOI: 10.1002/cyto.a.23570

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  12 in total

1.  Multiparameter Flow Cytometry for Detailed Characterization of Peritoneal Immune Cells from Patients with Ovarian Cancer.

Authors:  Jessica Vazquez; Dagna Sheerar; Aleksandar K Stanic; Manish S Patankar
Journal:  Methods Mol Biol       Date:  2022

2.  Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.

Authors:  Capucine Baldini; Francois-Xavier Danlos; Andreea Varga; Matthieu Texier; Heloise Halse; Severine Mouraud; Lydie Cassard; Stéphane Champiat; Nicolas Signolle; Perrine Vuagnat; Patricia Martin-Romano; Jean-Marie Michot; Rastislav Bahleda; Anas Gazzah; Lisa Boselli; Delphine Bredel; Jonathan Grivel; Chifaou Mohamed-Djalim; Guillaume Escriou; Laetitia Grynszpan; Amelie Bigorgne; Saloomeh Rafie; Alae Abbassi; Vincent Ribrag; Sophie Postel-Vinay; Antoine Hollebecque; Sandrine Susini; Siham Farhane; Ludovic Lacroix; Aurelien Parpaleix; Salim Laghouati; Laurence Zitvogel; Julien Adam; Nathalie Chaput; Jean-Charles Soria; Christophe Massard; Aurelien Marabelle
Journal:  J Exp Clin Cancer Res       Date:  2022-07-07

Review 3.  Key steps and methods in the experimental design and data analysis of highly multi-parametric flow and mass cytometry.

Authors:  Paulina Rybakowska; Marta E Alarcón-Riquelme; Concepción Marañón
Journal:  Comput Struct Biotechnol J       Date:  2020-03-31       Impact factor: 7.271

4.  Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring.

Authors:  Iole Macchia; Valentina La Sorsa; Irene Ruspantini; Massimo Sanchez; Valentina Tirelli; Maria Carollo; Giorgio Fedele; Pasqualina Leone; Giovanna Schiavoni; Carla Buccione; Paola Rizza; Paola Nisticò; Belinda Palermo; Stefania Morrone; Helena Stabile; Aurelia Rughetti; Marianna Nuti; Ilaria Grazia Zizzari; Cinzia Fionda; Roberta Maggio; Cristina Capuano; Concetta Quintarelli; Matilde Sinibaldi; Chiara Agrati; Rita Casetti; Andrea Rozo Gonzalez; Floriana Iacobone; Angela Gismondi; Filippo Belardelli; Mauro Biffoni; Francesca Urbani
Journal:  J Immunol Res       Date:  2020-04-12       Impact factor: 4.818

5.  CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.

Authors:  Boris Duchemann; Marie Naigeon; Edouard Auclin; Roberto Ferrara; Lydie Cassard; Jean-Mehdi Jouniaux; Lisa Boselli; Jonathan Grivel; Aude Desnoyer; François-Xavier Danlos; Laura Mezquita; Caroline Caramella; Aurelien Marabelle; Benjamin Besse; Nathalie Chaput
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

Review 6.  Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.

Authors:  Fenglong Bie; He Tian; Nan Sun; Ruochuan Zang; Moyan Zhang; Peng Song; Lei Liu; Yue Peng; Guangyu Bai; Bolun Zhou; Shugeng Gao
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

7.  Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.

Authors:  Michelle Rosenzwajg; Joe-Elie Salem; Lee S Nguyen; Marie Bretagne; Jennifer Arrondeau; Noel Zahr; Stephane Ederhy; Baptiste Abbar; Bruno Pinna; Yves Allenbach; Jean-Paul Mira; Javid Moslehi
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751

Review 8.  How to Translate DNA Methylation Biomarkers Into Clinical Practice.

Authors:  Wolfgang Wagner
Journal:  Front Cell Dev Biol       Date:  2022-02-23

9.  Effects of Platelet Agonists and Priming on the Formation of Platelet Populations.

Authors:  Alicia Veninga; Constance C F M J Baaten; Ilaria De Simone; Bibian M E Tullemans; Marijke J E Kuijpers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Thromb Haemost       Date:  2021-10-24       Impact factor: 6.681

10.  NCKAP1L defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation.

Authors:  Carla Noemi Castro; Michelle Rosenzwajg; Raphael Carapito; Mohammad Shahrooei; Martina Konantz; Amjad Khan; Zhichao Miao; Miriam Groß; Thibaud Tranchant; Mirjana Radosavljevic; Nicodème Paul; Tristan Stemmelen; Fabien Pitoiset; Aurélie Hirschler; Benoit Nespola; Anne Molitor; Véronique Rolli; Angélique Pichot; Laura Eva Faletti; Bruno Rinaldi; Sylvie Friant; Mark Mednikov; Hatice Karauzum; M Javad Aman; Christine Carapito; Claudia Lengerke; Vahid Ziaee; Wafaa Eyaid; Stephan Ehl; Fayhan Alroqi; Nima Parvaneh; Seiamak Bahram
Journal:  J Exp Med       Date:  2020-12-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.